NFL Biosciences (XPAR:ALNFL) Debt-to-Asset : 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Debt-to-Asset?

NFL Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.06 Mil. NFL Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. NFL Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €3.97 Mil. NFL Biosciences's debt to asset for the quarter that ended in Dec. 2023 was 0.02.

NFL Biosciences Debt-to-Asset Historical Data

The historical data trend for NFL Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Debt-to-Asset Chart

NFL Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.15

0.02

0.04

0.02

NFL Biosciences Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial			0.02	0.03	0.04	0.03	0.02

Competitive Comparison of NFL Biosciences's Debt-to-Asset

For the Biotechnology subindustry, NFL Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's Debt-to-Asset falls into.

NFL Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NFL Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.062	+	0)	/	3.971
	=	0.02

NFL Biosciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.062	+	0)	/	3.971
	=	0.02

NFL Biosciences (XPAR:ALNFL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NFL Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (XPAR:ALNFL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

82F:Germany

Address

199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170

Website

https://www.nflbiosciences.com/

NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines